↓ Skip to main content

Dove Medical Press

Article Metrics

The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, November 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
38 Mendeley
Title
The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD
Published in
International Journal of Chronic Obstructive Pulmonary Disease, November 2015
DOI 10.2147/copd.s93375
Pubmed ID
Authors

Alberto Papi, Paul Jones, Kirsten McAulay, Tammy McIver, Sanjeeva Dissanayake, Prashant Dalvi

Abstract

Inhaled corticosteroid/long-acting β2-agonist combination therapy is recommended in chronic obstructive pulmonary disease (COPD) patients at high risk of exacerbations. The EFFECT (Efficacy of Fluticasone propionate/FormotErol in COPD Treatment) trial is a Phase III, 52-week, randomized, double-blind study to evaluate the efficacy and safety of two doses of fluticasone propionate/formoterol compared to formoterol monotherapy in COPD patients with FEV1 ≥50% predicted and a history of exacerbations. The primary endpoint is the annualized rate of moderate and severe exacerbations. Secondary endpoints include pre-dose FEV1, EXACT-PRO (EXAcerbations of Chronic pulmonary disease Tool - Patient-Reported Outcome)-defined exacerbations, St George's Respiratory Questionnaire for COPD, COPD Assessment Test, and EXACT-Respiratory Symptoms total score. Lung-specific biomarkers (surfactant protein D and CC chemokine ligand-18) will be measured in a subset of patients to explore their relationship to other clinical indices in COPD and their predictive utility. Pneumonia will be diagnosed per criteria defined by the British Thoracic Society community acquired pneumonia guideline, primarily by radiological confirmation and, additionally, using clinical criteria when a chest radiograph cannot be obtained. Serial measurements of serum potassium, vital signs and electrocardiograms, 24-hour Holter monitoring, and 24-hour urinary cortisol measurement will be performed in a subset of patients in addition to conventional safety assessments.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 3%
Brazil 1 3%
Unknown 36 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 9 24%
Student > Bachelor 6 16%
Student > Ph. D. Student 4 11%
Other 4 11%
Student > Doctoral Student 4 11%
Other 10 26%
Unknown 1 3%
Readers by discipline Count As %
Medicine and Dentistry 20 53%
Nursing and Health Professions 3 8%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Psychology 2 5%
Economics, Econometrics and Finance 2 5%
Other 6 16%
Unknown 3 8%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 December 2015.
All research outputs
#4,783,306
of 6,771,968 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#540
of 833 outputs
Outputs of similar age
#174,625
of 283,906 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#37
of 54 outputs
Altmetric has tracked 6,771,968 research outputs across all sources so far. This one is in the 25th percentile – i.e., 25% of other outputs scored the same or lower than it.
So far Altmetric has tracked 833 research outputs from this source. They receive a mean Attention Score of 3.5. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 283,906 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.